Our broad range of tumor lines ensures a wide variety of testing alternatives for your agent. Our xenograft model portfolio is evaluated on a regular basis for response to standards of care and this data is available for designing combination studies.
Our scientific staff can assist in selecting the most appropriate model for your agent. Complete profiling of agents can be carried out in a variety of tumor types or in combination with the appropriate clinical agent.
Efficacy evaluation can be combined with:
Hematology (CBC/Diff) analysis
Pharmacokinetic or bioavailability sampling and analysis
Histopathology or tissue sampling
Biomarker screening, sampling or evaluation
Schedule Model Selection Discussion »